|
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study
Summary
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. It is an observational registry designed to evaluate XIENCE V EECSS safety and effectiveness in real world settings up to 1 year after implantation.
Description
Winthrop-University Hospital - Division of Cardiology is one of the participating site to enroll subjects receiving the XIENCE V EECSS during percutaneous coronary intervention. The objective is to determine clinical device and procedural success during commercial use in real world settings. Up to 8,000 subjects are consecutively enrolled at up to 275 sites across USA. Clinical follow-up is done at 14, 30, 180 days and 1 year as telephone contacts or office visits.
Inclusion/exclusion
Eligibility Criteria: - Subjects agree to participate in the study by signing the IRB approved informed consent form. - Subjects who receive the XIENCE V EECSS during percutaneous coronary intervention procedure.
Principal Investigator
Srihari Naidu, MD
Department
Division of Cardiology
Email
ssnaidu@winthrop.org
Other Contact
For more information please call Research Coordinator at 516-663-2929.
|
